---

---

tags : Disease    symbols : ALNY   

save search

---

Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.53 690K |

Manufacturing

| -11.92% | O: 0.37% H: 0.74% C: 0.28%
BMY | $49.2 0.12% 2.9M |

Health Technology

| -1.23% | O: -0.18% H: 0.48% C: -1.91%
ABBV | News | $170.19 1.37% 1.6M |

Health Technology

| -2.99% | O: 0.8% H: 0.0% C: 0.0%
SNY | News | $47.5 0.74% 450K |

Health Technology

| 0.16% | O: -0.06% H: 0.0% C: 0.0%
GILD | $67.36 0.61% 1.2M |

Health Technology

| -10.07% | O: 0.32% H: 0.11% C: -1.55%
ALNY | $148.99 2.2% 130K |

Health Technology

| -13.91% | O: -2.63% H: 0.98% C: -1.75%
liver disease therapeutics market

---

Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $742.04 1.46% 540K |

Health Technology

| 15.92% | O: -0.51% H: 0.37% C: 0.32%
MDGL | $222.745 4.34% 130K |

Health Technology

| -8.44% | O: 1.29% H: 0.35% C: -3.04%
HEPA | $1.39 -1.42% 27K |

Health Technology

| -32.54% | O: -0.48% H: 7.69% C: 1.44%
ALT | $8.0 7.1% 1.2M |

Commercial Services

| -25.6% | O: -0.8% H: 6.02% C: 0.6%
ALNY | $148.99 2.2% 130K |

Health Technology

| -20.73% | O: 0.46% H: 3.04% C: 2.67%
ETNB | $9.32 0.11% 240K |

Health Technology

| -14.74% | O: 1.19% H: 0.63% C: -0.72%
liver disease companies key growth market

---

Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 600K |

Health Technology

| -10.43% | O: 0.4% H: 1.29% C: 1.29%
SNY | News | $47.5 0.74% 450K |

Health Technology

| -11.67% | O: 1.43% H: 0.64% C: -0.09%
ALNY | $148.99 2.2% 130K |

Health Technology

| -11.08% | O: -1.28% H: 0.58% C: -1.46%
disease alzheimer’s positive results

---

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $47.5 0.74% 450K |

Health Technology

| -12.21% | O: 0.02% H: 0.0% C: 0.0%
REGN | News | $906.305 0.68% 87K |

Health Technology

| 25.28% | O: 0.05% H: 1.33% C: 0.38%
ALNY | $148.99 2.2% 130K |

Health Technology

| -26.03% | O: 5.53% H: 5.23% C: -2.49%
disease alzheimer’s positive results

---

Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-04-26 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 600K |

Health Technology

| -17.96% | O: -1.46% H: 0.0% C: 0.0%
SNY | News | $47.5 0.74% 450K |

Health Technology

| -19.49% | O: 0.53% H: 0.0% C: 0.0%
REGN | News | $906.305 0.68% 87K |

Health Technology

| 14.0% | O: -0.99% H: 0.38% C: -0.48%
ALNY | $148.99 2.2% 130K |

Health Technology

| -27.88% | O: -0.76% H: 0.33% C: -1.54%
disease report alzheimer’s positive

---

Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-04-26 (Crawled : 23:00) - biospace.com/
SNYNF | News | $92.7 600K |

Health Technology

| -17.96% | O: -1.46% H: 0.0% C: 0.0%
SNY | News | $47.5 0.74% 450K |

Health Technology

| -19.49% | O: 0.53% H: 0.0% C: 0.0%
REGN | News | $906.305 0.68% 87K |

Health Technology

| 14.0% | O: -0.99% H: 0.38% C: -0.48%
ALNY | $148.99 2.2% 130K |

Health Technology

| -27.88% | O: -0.76% H: 0.33% C: -1.54%
disease report alzheimer’s positive

---

Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
SNY | News | $47.5 0.74% 450K |

Health Technology

| -2.28% | O: 0.79% H: 0.0% C: 0.0%
REGN | News | $906.305 0.68% 87K |

Health Technology

| 20.22% | O: -0.09% H: 0.59% C: -0.21%
ALNY | $148.99 2.2% 130K |

Health Technology

| -34.56% | O: -2.68% H: 0.6% C: -7.83%
treatment fda disease children review

---

Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
Published: 2022-07-27 (Crawled : 22:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380 |

Health Technology

| 41.37% | O: 2.86% H: 0.0% C: 0.0%
SNY | News | $47.5 0.74% 450K |

Health Technology

| -7.93% | O: 0.68% H: 0.0% C: 0.0%
REGN | News | $906.305 0.68% 87K |

Health Technology

| 53.11% | O: 0.17% H: 0.53% C: -1.11%
ALNY | $148.99 2.2% 130K |

Health Technology

| 2.69% | O: -3.5% H: 6.04% C: 4.76%
rare liver disease

---

n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
ALNY | $148.99 2.2% 130K |

Health Technology

| -1.81% | O: -2.0% H: 0.0% C: 0.0%
rare technology therapeutics disease

---

Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | News | $47.5 0.74% 450K |

Health Technology

| -6.63% | O: -0.59% H: 1.12% C: 0.93%
ALNY | $148.99 2.2% 130K |

Health Technology

| -26.96% | O: -5.24% H: 2.44% C: -0.93%
alzheimer treatment application disease alzheimer’s alzheimer's disease alzheimer's

---

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | News | $127.76 2.0% 1.3M |

Health Technology

| 10.26% | O: -0.47% H: 0.0% C: 0.0%
LLY | News | $742.04 1.46% 540K |

Health Technology

| 178.04% | O: -0.49% H: 0.0% C: 0.0%
ALNY | $148.99 2.2% 130K |

Health Technology

| -17.43% | O: -2.06% H: 0.0% C: 0.0%
disease liver disease phase 1 liver trial

---

Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | News | $127.76 2.0% 1.3M |

Health Technology

| 43.14% | O: 0.9% H: 0.72% C: 0.58%
LLY | News | $742.04 1.46% 540K |

Health Technology

| 211.18% | O: 0.58% H: 0.42% C: 0.38%
ALNY | $148.99 2.2% 130K |

Health Technology

| -20.41% | O: 0.45% H: 0.0% C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3

---

Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | News | $127.76 2.0% 1.3M |

Health Technology

| 51.55% | O: -0.39% H: 0.27% C: -0.21%
LLY | News | $742.04 1.46% 540K |

Health Technology

| 228.44% | O: -0.02% H: 0.44% C: -0.53%
ALNY | $148.99 2.2% 130K |

Health Technology

| -14.87% | O: 0.08% H: 1.01% C: 0.9%
disease liver disease treatment phase 2 liver trial

---

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.595 164.08% 13M |

AGBA | $2.61 108.8% 41M |

Finance

CZOO | $9.32 86.77% 18M |

EDBL | News | $6.7 78.19% 1.7M |

MTC | $2.28 46.15% 2.6M |

Technology Services

OPRT | News | $3.14 39.56% 7.6M |

Finance

VNRX | $0.8 33.33% 2.9M |

Health Technology

MLEC | $1.865 33.21% 2.4M |

n/a

PALI | $6.37 29.21% 21M |

Manufacturing

LOCL | $3.33 27.59% 43K |

---

Your saved searches

---